FocalTherics partners with MellingMedical to bring HIFU to VA system
FocalTherics (Nasdaq: FOCL) has signed a distribution agreement with MellingMedical, an SBA-verified Service-Disabled Veteran-Owned Small Business, to make its Focal One Robotic High Intensity Focused Ultrasound platform available across the Veterans Affairs and Department of Defense healthcare systems. The deal gives federal healthcare facilities a procurement route for the device through MellingMedical's existing VA Federal Supply Schedule.
The announcement targets a sizeable clinical population: FocalTherics says nearly 500,000 veterans are currently receiving prostate cancer treatment or care within the Veterans Healthcare System, and that men in that system are diagnosed with prostate cancer at roughly twice the rate of the general population. Prostate cancer accounts for approximately 30% of new cancer diagnoses among men receiving care at VA facilities, according to the company.
The deal
Focal One Robotic HIFU uses focused ultrasound energy to ablate prostate tissue without incisions or radiation. FocalTherics positions the technology as a focal therapy approach intended to treat localised disease while reducing the risk of side effects such as incontinence and erectile dysfunction that can accompany surgery or radiotherapy. The company describes itself as a global leader in robotic focal therapy, though competitor platforms exist in the broader therapeutic ultrasound and focal ablation space.
MellingMedical's supply schedule already covers all 172 VA Medical Centres, 1,138 VA outpatient clinics, 95 DoD medical facilities, and associated government health services. Ryan Rhodes, chief executive of FocalTherics, said the partnership would expand patient access to Focal One "without the long-lasting effects of surgery or radiation." The company added no financial terms or volume commitments to the announcement.
The move is partly enabled by the 2022 Cleland-Dole Act, which directed the Department of Veterans Affairs to advance comprehensive prostate cancer care and has increased federal focus on the indication over the past four years.
Market context
The agreement marks a notable channel extension for FocalTherics, but investors should note that listing a device on a federal supply schedule does not guarantee purchase orders or generate immediate revenue. Adoption within the Veterans Healthcare System depends on individual facility budgets, clinical champions, and broader VA procurement policy, factors that lie outside the company's control and are flagged in its own forward-looking statement disclosures.
More broadly, the focal therapy segment is operating in a competitive urology landscape. Whole-gland treatments, including robot-assisted radical prostatectomy and stereotactic body radiotherapy, remain the standard of care for most localised prostate cancer in the United States. Focal HIFU has won regulatory clearance and growing clinical acceptance, but adoption has been gradual, partly because long-term comparative data versus surgery are limited. The VA's emphasis on quality-of-life outcomes for veterans could, however, make focal therapy a more attractive option than in the broader civilian market, where surgical tradition tends to be stronger.
For FocalTherics, successfully penetrating a centralised federal healthcare network would offer a meaningful volume opportunity if clinical adoption follows. The company's next milestones to watch will be whether VA facilities begin placing orders and whether it can present real-world outcomes data from the veteran population to support wider rollout.